Skip to main content
Lotus Pharm logo

Lotus Pharm — Investor Relations & Filings

Ticker · 1795 ISIN · TW0001795003 LEI · 984500BEECDBC04KP716 TW Manufacturing
Open in API
Filings indexed 2,730 across all filing types
Latest filing 2025-08-15 Investor Presentation
Country TW Taiwan
Listing TW 1795

About Lotus Pharm

http://www.lotuspharm.com.tw

Lotus Pharmaceutical Co., Ltd. is a global specialty organization focused on the development, manufacturing, and commercialization of high-barrier generic and specialty medicines. The company specializes in complex generics, with a primary focus on oncology, immunology, and addiction treatment. Its portfolio includes technically demanding products such as Lenalidomide, Suboxone, Nintedanib, and Vinorelbine, as well as an advancing pipeline of biosimilars and 505(b)(2) oncology candidates. Utilizing an integrated R&D and manufacturing platform, the company executes a "2x2" growth strategy centered on dual market expansion and product diversification. Its commercial footprint spans over 90 markets globally, maintaining a strong presence in the Asia-Pacific region and the United States. The company prioritizes high technical entry barriers and cost-effective therapeutic solutions to improve global patient access to essential medications.

Recent filings

Filing Released Lang Actions
114年08月法人說明會簡報
Investor Presentation Classification · 95% confidence The document is a listing from a public information observation station showing scheduled dates and details for corporate investor presentations (法人說明會) for company code 1795 (美時). It includes dates, times, locations (online), and links to presentation materials in PDF format. The content focuses on investor presentations about the company's quarterly financial and operational status. The document is short (1030 characters) and primarily serves as an announcement or schedule of investor presentations rather than the presentations themselves or detailed financial reports. Therefore, the best classification is Investor Presentation (IP).
2025-08-15 Chinese
114年第2季海外子公司投資
Regulatory Filings Classification · 95% confidence The document is a detailed tabular disclosure of investment holdings and investment income/losses related to overseas subsidiaries for a specific quarter (114年2季, which corresponds to the second quarter of the 114th year in the Taiwanese calendar, roughly 2025). It includes financial figures such as original investment amounts, investment balances, and recognized investment gains or losses. The document is relatively short (2765 characters) and appears to be a regulatory disclosure of investment details rather than a full financial report. There is no indication that this is a full annual or interim report, nor is it a simple announcement or certification. The content aligns with a regulatory filing providing detailed investment information as required by securities regulators. Therefore, the best classification is Regulatory Filings (RNS).
2025-08-14 Chinese
114年第2季大陸投資
Regulatory Filings Classification · 95% confidence The document is a detailed tabular disclosure of the company's investments in mainland China, including capital amounts, investment methods, and related notes. It includes financial figures and regulatory references to investment limits by the Ministry of Economic Affairs Investment Commission. The document length is short (1438 characters) and it is a specific regulatory disclosure about overseas investments rather than a full financial report or announcement. It does not contain comprehensive financial statements or management discussion. This type of disclosure typically falls under Regulatory Filings (RNS) as it is a compliance-related investment disclosure without being a full report or announcement of a report.
2025-08-14 Chinese
公告本公司董事會決議通過114年第二季財務報告
Interim / Quarterly Report Classification · 95% confidence The document is a public announcement from a listed company (1795 美時) reporting the board of directors' approval of the Q2 financial report for the period 114/01/01 to 114/06/30 (which corresponds to the second quarter). It includes cumulative financial figures such as revenue, gross profit, operating profit, net profit, EPS, total assets, liabilities, and equity. The document is relatively short (922 characters) and appears to be a formal announcement of the approval of the interim financial report rather than the full report itself. Given the content and the nature of the announcement, this fits the category of an Interim / Quarterly Report (IR), as it contains substantive financial data for a period shorter than a full fiscal year. H1 2025
2025-08-11 Chinese
114年7月背書保證與資金貸與
Regulatory Filings Classification · 95% confidence The document is a financial disclosure from a listed company (美時) providing details on fund lending balances and endorsement guarantees for the current and previous month, including limits and cumulative amounts. It is a short report focused on specific financial data related to intercompany and subsidiary transactions, without broader financial statements or management discussion. The length is only 619 characters, indicating it is a brief regulatory disclosure rather than a full financial report. There is no indication of an earnings release, annual or interim report, or other detailed filings. This type of document fits best under Regulatory Filings (RNS), which covers miscellaneous regulatory disclosures that do not fit other categories.
2025-08-11 Chinese
114年7月營業收入
Fund Information / Factsheet Classification · 90% confidence The document is a revenue summary report provided by a listed company, showing monthly and cumulative net operating revenue figures with comparisons to the previous year. It includes notes on accounting standards and reporting practices but does not contain comprehensive financial statements or detailed analysis. The document length is short (781 characters) and it primarily presents summarized financial data without the depth expected in an interim or annual report. It is not an announcement of a report publication but a brief financial summary. This fits best with the category 'Fund Information / Factsheet (FS)', which covers brief summaries of key company financials and market info.
2025-08-11 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.